Vergelijking

Cerebrolysin vs. Selank

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

96889-70-6

129954-34-3

Molecuulmassa

geen gegevens

751.85 g/mol

Halfwaardetijd

geen gegevens

0.3 h

Sequentie

geen gegevens

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Werkingsmechanisme

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Selank

Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Cerebrolysin	Selank
Oostenrijk	Op recept	—
CN	Op recept	—
Duitsland	Onduidelijk	Niet goedgekeurd
RU	Op recept	Op recept
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Cerebrolysin

Volledige vermelding →

Selank

Volledige vermelding →

Frequently asked questions

What is the difference between Cerebrolysin and Selank?: Cerebrolysin is classified as "Onderzoek (overig)", while Selank is classified as "Onderzoek (overig)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Selank?: The highest available evidence level is "Humane RCT" for Cerebrolysin and "Humane studie" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Selank in Germany and the United States?: Duitsland: Cerebrolysin — Onduidelijk, Selank — Niet goedgekeurd. Verenigde Staten: Cerebrolysin — Niet goedgekeurd, Selank — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Selank

Oostenrijk

Op recept

—

Op recept

—

Duitsland

Onduidelijk

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Cerebrolysin and Selank?

Cerebrolysin is classified as "Onderzoek (overig)", while Selank is classified as "Onderzoek (overig)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Selank?

The highest available evidence level is "Humane RCT" for Cerebrolysin and "Humane studie" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Selank in Germany and the United States?

Duitsland: Cerebrolysin — Onduidelijk, Selank — Niet goedgekeurd. Verenigde Staten: Cerebrolysin — Niet goedgekeurd, Selank — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.